Mithramycin impairs the release of 45Ca from bone induced by prostaglandin E2 or multiple myeloma sera: Implications for a novel means of local tumor control

Oncology (Switzerland)

Volumn 39, Issue 2, 1982, Pages 72-77

  Anderson, K M ^a   Rubenstein, M ^a   Sky Peck, H ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

45Ca; Multiple myeloma; Prostaglandin; Rat bone

Indexed keywords

CALCIUM 45; MITHRAMYCIN; PROSTAGLANDIN E2; RADIOISOTOPE;

ANIMAL EXPERIMENT; BLOOD AND HEMOPOIETIC SYSTEM; BONE; DRUG ABSORPTION; MULTIPLE MYELOMA; RAT; SERUM;

ANIMAL; BONE AND BONES; CALCIUM; HUMAN; IN VITRO; MULTIPLE MYELOMA; OSTEOCLASTS; PLICAMYCIN; PROSTAGLANDINS E; RATS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0020026526     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000225610     Document Type: Article

References (42)

1. Stamp, T.C.B.; Child, J.A.; Walker, P.G.: Treatment of osteolytic myelomatosis with mithramycin. Lancet 719-722 (1975).
2. Persky, L.; Guerrier. K.; Rabin, R.; Albert, D.J.: Mithramycin and metastatic carcinoma of the prostate. J. Urol. 104: 884-887 (1970).
3. Anderson, K.M.; Bonomi. P.: Mithramycin and local control of osteolytic metastases (Clinical Research. Society of Toronto, Toronto 1977).
4. Koíman. S.; Eisenstein, R.: Mithramycin in the treatment of disseminated cancer. Cancer Chemother. Rep. 32: 77-96 (1963).
5. Parsons, V.; Baum. M.; Self, M.: Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease. Br. med. J. 1: 474-477 (1967).
6. Perlia, C.P.; Gubisch, N.J.; Wolter. J.; Edelberg, D.; Dederick, M.M.; Taylor, S. G.: Mithramycin treatment of hypercalcemia. Cancer 25: 389-394 (1970).
7. Slayton. R.E.; Shnider, B.L; Elias, E.; Horton, J.; Perlia, C.P.: New approaches to the treatment of hypercalcemia. The effect of short-term treatment with mithramycin. Clin. Pharmacol. Ther. 12: 833-837 (1971).
8. Dietz, A.: Mithramycin-Behandlung einer Hyperkalzemie bei metastasierendem Osteosarkom. Medsche Welt, Stuttg. 26: 1242-1245 (1975).
9. Singer. F. R.; Neer. R.M.; Murray, T.M.; Keutmann, H.T.; Deftos, L.J.; Potts. J.T.: Mithramycin treatment of intractable hypercalcemia due to parathyroid carcinoma. New Engl. J. Med. 283: 634-636 (1970).
10. Ryan, W. G.; Schwartz, T. B.; Perlia. C. P.: Effects of mithramycin on paget's disease of bone. Ann. intern. Med. 70: 549-557 (1969).
11. Lebbin. P.; Ryan, W.G.; Schwartz, T. B.: Outpatient treatment of Paget's disease of bone with mithramycin. Ann. intern. Med. 81: 635-637 (1974).
12. Conrad, M.E.; Carpenter, J.T.; Todd, J.N.; Murad, T.M.: Mithramycin in the treatment of systemic mastocytosis. Ann. intern. Med. 83: 659-660 (1975).
13. Edwards, C.R.W.; Besser, G.M.: Mithramycin treatment of malignant hypercalcemia. Br. med. S. iii: 167-168 (1968).
14. Goldberg, I. H.: Mode of action of antibiotics. 11. Drugs affecting nucleic acid and protein synthesis. Am. J. Med. 39: 722-752 (1965).
15. Yarbro, J.W.; Kennedy, B.J.; Barnum. C. P.: Mithramycin inhibition of ribonucleic acid synthesis. Cancer Res. 26: 36-39 (1966).
16. Northrop, G.; Taylor. S.G.; Northrop, R.L.: Biochemical effects of mithramycin on cultured cells. Cancer Res. 29: 1916-1919 (1969).
17. Robins. P. R.; Jowsey, J.: Effect of mithramycin on normal and abnormal bone turnover. J. Lab. clin. Med. 82: 576-586 (1973).
18. Minkin, C.: Inhibition of parathyroid hormone stimulated bone resorption in vitro by the antibiotic mithramycin. Calcif. Tissue Res. 13: 249-257 (1973).
19. Ryan, W.G.; Schwartz. T. B.; Northrop, G.: Further observations on the treatment of Paget's disease of bone with mithramycin. Abstr. 52nd Ann. Session. American College of Physicians, 1971.
20. Mundy, G.R.; Raisz, L.G.; Cooper. R.A.; Schechter, G.P.; Salmon. S. E.: Evidence for the secretion of osteoclast stimulation factor in myelomas. New Engl. J. Med. 291: 1041-1046 (1974).
21. Stern. P.; Raisz, L.O.: Organ culture of bone: in Simmons. Kumin, Skeletal research, pp. 21-59 (Academic Press, New York 1979).
22. Klein. D.C.; Raisz. L.G.: Prosglandins. Stimulation of bone Resorption in tissue culture. Endocrinology 86: 1436-1440 (1970).
23. 2. J. exp. Med. 136: 1329-1343 (1972).
24. Dietrich. J. W.; Goodson. J. M.; Raisz, L.G.: Stimulation of bone resorption by various prostaglandins in organ culture. Prostaglandins 10: 231-240 (1975).
25. Gomes, B.C.; Hausmann, E.; Weinfeld, N.: DeLucca, C.: Prosglandins. Bone resorption stimulating factors released from monkey gingiva. Calcif. Tissue Res. 19: 285-293 (1976).
26. Canfield, R.: Rosner. W.; Skinner. J.; McWhorter. J.: Diphos- phonate therapy of Paget's disease of bone. J. clin. Endocr. Metab.44: 96-106(1977).
27. Frijlink, W.B.; Bijvoet, O.L.M.; te Velde. J.; Heynen, G.: Treatment of Paget's disease with (3-amino-1-hydroxypropyl- idene)-1.1 -biphosphate. Lancet i: 799-803 (1979).
28. Siris, E.S.; Sherman. W.H.; Baguiron, D.C.; Schlattere. J.P.; Osserman. E.F.; Canfield. R.E.: Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. New Engl. J. Med.302: 310-315 (1980).
29. van Breukelen. F.J.M.; Bijvoet. O.L.M.; van Oosterom, A.T.: Inhibition of osteolytic bone lesions by (3-amino-1 -hydroxy- propylidene)-l,l-biphosphonate. Lancet i: 803-805 (1979).
30. Davies. J.; Trask, C.; Soubam. R.L.: Effect of mithramycin on widespread painful bone metastases in cancer of the breast. Cancer Treatm. Rep. 63: 1835-1838 (1979).
31. Coombes, R.C.; Munro. N.; Neville, A.; Guzet, J.C.; Ford, H.T.; Nash, A.G.; Baker, J. W.; Prowies, T.J.: Agents affecting osteolysis in patients with breast cancer. Cancer Chemother. Pharm. 3: 41-44 (1979).
32. Glasko, C.S.B.; Bonnet. A.: Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins. Nature. Lond. 263: 508-510(1976).
33. Bennett. A.: Simpson, J.S.; McDonald. A.M.; Stamford. I.F.: Breast cancer, prostaglandins, and bone metastases. Lancet i: 1218-1220 (1975).
34. Tashjian, A.H.; Voelkel. E.F.; Goldhabcr, P.; Levine, L.: Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglandin-producting fibrosarcoma. Prostaglandins 3: 515-524 (1973).
35. Dowsett. M.; Easty, G.C.; Powles, T.J.; Easty, D.M.; Neville. A.M.: Human breast tumour-induced osteolysis and prostaglandins. Prostaglandins 11: 447-455 (1976).
36. Powles, T.J.; Dowsett, M.; Easty, D.M.; Easty, G.C.; Neville, A.M.: Breast cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet i: 608-610 (1976).
37. Galasko. C.S. B.; Bennett. A.: Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins. Nature. Lond. 263: 508-510 (1976).
38. Folkman, J.; Cotran. R.: Relation of vascular proliferation to tumor growth. Int. Rev. exp. Path. 16: 207-248 (1976).
39. Kuettner. K.E.; Hiti. J.; Eisenstein, R.; Harper, E.: Collagenase inhibition by cationic proteins derived from cartilage and aorta. Biochem. biophys. Res. Commun. 72: 40 - 46 (1976).
40. Kamo. I.: Friedman. H.: Immunosuppression and the role of suppressive factors in cancer. Adv. Cancer Res. 25: 271-321 (1977).
41. Galasko, C.S.B.: Mechanism of bone destruction in the development of skeletal metastases. Nature, Lond. 263: 507-508 (1976).
42. Willis. R.A.: Secondary tumours of bones; in The spread of tumours in the human body; 3rd ed. Chap. 24, pp. 229-250 (Buttersworths, London 1973).